FDA.reportPublic FDA data

mitapivat 20 MG 4-Week Pack

RxCUI
2594741
RxNorm name
mitapivat 20 MG 4-Week Pack
Display name
mitapivat 20 MG 4-Week Pack
Full name
mitapivat 20 MG 4-Week Pack
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:57

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PYRUKYNDMITAPIVATAgios Pharmaceuticals, Inc.4ccee896-e313-4c6c-9674-b4746ada0a902026-06-30Warnings, Adverse reactionsExact identifier
rxcui: 2594741

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
4ccee896-e313-4c6c-9674-b4746ada0a90{56 (mitapivat 20 MG Oral Tablet) } Pack [GPCK] · mitapivat 20 MG 4-Week Pack [PSN] · mitapivat 20 MG 4-Week Pack [SY]39These highlights do not include all the information needed to use PYRUKYND safely and effectively. See full prescribing information for PYRUKYND. PYRUKYND ® (mitapivat) tablets, for oral use Initial U.S. Approval: 202220260422